Business Wire

REPLY: Shareholders’ Meeting approves the 2020 Financial Statements

26.4.2021 15:07:00 EEST | Business Wire | Press release

Share

The General Shareholders’ meeting of Reply S.p.A. [MTA, STAR: REY] today approved the Financial Statements for the financial year 2020, confirming the distribution of a gross dividend of €0.56 per share.

The dividend will be paid on 5 May 2021, with dividend date set on 3 May 2021 (record date on 4 May 2021).

2020 Financial Statement

The Reply Group closed the 2020 financial year with a consolidated turnover of €1,250.2 million, recording a 5.7% increase compared to €1,182.5 million for the 2019 financial year.

Consolidated EBITDA was €207.9 million, up 8.7% compared to €191.3 million in 2019.

Consolidated EBIT, from January to December, was €169.5 million, up 9.1% compared to €155.3 million at December 2019.

The Group net profit was at €123.6 million, up 8.6% compared to €113.9 million recorded in 2019.

The Shareholders’ Meeting also approved the following resolutions, in accordance with the proposal of the Board of Directors:

Appointment of the Board of Directors and the Board of Statutory Auditors for the three-year period 2021-2023

The Shareholders’ Meeting appointed the new members to the Board of Directors and the Board of Statutory Auditors for the three-year period 2021-2023 based on the submitted list of candidates.

The following have been appointed as Directors:

- Mario Rizzante (Chairman), Tatiana Rizzante, Filippo Rizzante, Daniele Angelucci, Marco Cusinato, Elena Previtera and Patrizia Polliotto (who declared to comply with the independence requirements set forth in article 148 of the TUF [Testo unico sulla finanza – Financial Act] and the Corporate Governance Code), drawn from the majority list submitted by the shareholder Alika S.r.l. (holder of a 39.754% stake in Reply S.p.A.'s share capital), and obtained the highest number of votes (76.709% of votes obtained);

- Secondina Giulia Ravera and Francesco Umile Chiappetta, who declared to comply with the independence requirements set forth in article 148 of the TUF and the Corporate Governance Code, drawn from the minority list submitted by a group of investors (holding a total stake of 3.503% of Reply S.p.A.'s share capital).

The appointed Board of Statutory Auditors consists of three standing members and two alternates:

- Ciro Di Carluccio (Chairman) and Giancarla Branda (Alternate Auditor), who declared to comply with the independence requirements set forth in article 148 of the TUF and the Corporate Governance Code, drawn from the minority list submitted by a group of investors (holding a total stake of 3.503% of Reply S.p.A.'s share capital);

- Piergiorgio Re (Standing Auditor), Ada Garzino Demo (Standing Auditor), Stefano Barletta (Alternate Auditor), who declared to comply with the independence requirements set forth in article 148 of the TUF and the Corporate Governance Code, drawn from the majority list submitted by the shareholder Alika S.r.l. (holder of a 39.754% stake in Reply S.p.A.'s share capital), and obtained the highest number of votes (75.741% of votes obtained).

- The curricula vitae of the Directors and Statutory Auditors, as well as the additional documentation required by current legislation, are available in the investors’ section of the company website www.reply.com

Approval of the Programme for the Acquisition and/or Disposal of Own Shares

The Shareholders’ Meeting authorised a new share buyback programme, while withdrawing the current one approved at the Shareholders’ Meeting of 21 April 2020: the main objective of this programme is the purchase of shares to implement the stock incentive plans, transactions aimed at the acquisition of equity investments, extraordinary financial transactions and/or the conclusion of agreements with strategic partners.

The authorization has a duration of 18 months from the date of the resolution, for a maximum of 7,411,457 ordinary shares (equal to 19.8107% of the current share capital) with a nominal value of €0.13 each for a maximum nominal value of €963,489.41, within the limit of a maximum financial commitment of €300,000,000. The purchase price may not be lower than the nominal value (currently €0.13) and higher than the official trading price recorded on the MTA market on the day before the purchase, increased by 20%.

Approval of the Remuneration Report

The Shareholders' Meeting also approved Section II of the Remuneration Report drafted pursuant to Article 123-ter of Legislative Decree 58/1998.

Approval of the delegation of powers to the Board of Directors to increase the share capital with a share premium, subject to withdrawal of the previous delegation of powers granted on 21 April 2016

The Shareholders' Meeting withdrew the mandate conferred to the Board of Directors to increase the share capital, which expired on April 21, 2021, and reauthorized the Board of Directors, in compliance to article 2443 of the Italian Civil Code, to increase the share capital with a share premium and the exclusion of shareholders' option rights in compliance to article 2441, paragraph 4, up to a maximum nominal amount of 390,000.00 Euros through the issue of a maximum of 3,000,000 new Reply S.p.A. ordinary shares with a nominal value of 0.13 Euros each, to be executed in one or more tranches, therefore in a divisible manner, for a maximum period of five years, to be paid through contributions in kind of shares in other companies, having a similar or analogous purpose to the company's or in any case functional to the development of the business. The Shareholders' Meeting consequently resolved to amend Article 5 (Share Capital) of the Articles of Association

The manager in charge of drafting the company's financial reports, Dr Giuseppe Veneziano, declares in accordance with Paragraph 2 of Article 154-bis of the Consolidated Finance Act, that the accounting information contained in this press release corresponds to the company's records, ledgers and accounting records.

Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services www.reply.com

April 26, 2021

This press release is a translation, the Italian version will prevail.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts

Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594

Investor Relation Contacts

Reply
Riccardo Lodigiani
r.lodigiani@reply.com
Tel. +390117711594

Michael Lueckenkoetter
m.lueckenkoetter@reply.com
Tel. +49524150091017

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye